{"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"71"},{"groupId":"BG004","value":"88"},{"groupId":"BG005","value":"44"},{"groupId":"BG006","value":"255"}],"units":"Participants"}],"groups":[{"description":"Included all participants who received oral glasdegib in combination with LDAC in phase 1B portion.","id":"BG000","title":"Phase 1B: Glasdegib + LDAC"},{"description":"Included all participants who received oral glasdegib in combination with decitabine in phase 1B portion.","id":"BG001","title":"Phase 1B: Glasdegib + Decitabine"},{"description":"Included all participants who received oral glasdegib in combination with cytarabine/daunorubicin in phase 1B portion.","id":"BG002","title":"Phase 1B: Glasdegib + Cytarabine/Daunorubicin"},{"description":"Participants received 1-2 cycles of induction (glasdegib and daunorubicin/cytarabine), followed by 2-4 cycles of consolidation (glasdegib and high dose cytarabine) and a maximum of 6 cycles of maintenance (glasdegib alone). Daunorubicin was given on Days 1-3 QD at a dose of 60 mg/m\\^2/day by IV together with cytarabine on Days 1-7 at a dose of 100 mg/m\\^2/day by continuous IV infusion for each cycle of induction. Cytarabine was given on Days 1, 3, and 5 at a dose of 1 g/m\\^2 administered as a 3-hour IV infusion every 12 hours (2 g/m\\^2/day) for each cycle of consolidation. Glasdegib tablets 100 mg QD was started on induction Cycle 1/Day -3 and administered continuously QD thereafter for the duration of the study. A cycle was defined as 28 days.","id":"BG003","title":"Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin"},{"description":"Participants received oral doses of glasdegib tablets 100 mg QD in 28-day cycles on a continuous basis, starting on Day 1 of Cycle 1. LDAC was given at a dose of 20 mg subcutaneously BID on Days 1-10 of the 28-day cycles.","id":"BG004","title":"Phase 2 Unfit: Glasdegib 100 mg + LDAC"},{"description":"Participants received LDAC subcutaneously at a dose of 20 mg BID on Days 1-10 of the 28-day cycles.","id":"BG005","title":"Phase 2 Unfit: LDAC Alone"},{"description":"Total of all reporting groups","id":"BG006","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"6.5","value":"75.8"},{"groupId":"BG001","spread":"4.4","value":"75.0"},{"groupId":"BG002","spread":"12.7","value":"54.9"},{"groupId":"BG003","spread":"9.6","value":"61.9"},{"groupId":"BG004","spread":"6.2","value":"76.2"},{"groupId":"BG005","spread":"4.9","value":"74.5"},{"groupId":"BG006","spread":"13.9","value":"66.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"19"},{"groupId":"BG005","value":"18"},{"groupId":"BG006","value":"85"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"43"},{"groupId":"BG004","value":"69"},{"groupId":"BG005","value":"26"},{"groupId":"BG006","value":"170"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}